Streetbeat News

ARQT

Arcutis Biotherapeutics, Inc.

https://www.arcutis.com

Industry

Biotechnology

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Open

9.84

Mkt cap

1.1B

Volume

2.9M

High

10.04

P/E Ratio

-5.54

52-wk high

13.17

Low

9.11

Div yield

N/A

52-wk low

1.76

Several stocks are experiencing significant pre-market trading movements. XORTX Therapeutics, Urgent.ly, Aravive, Wheeler Real Estate Investment Trust, Intelligent Living Application Group, SEALSQ Corp, American Well Corporation, Knight-Swift Transportation Holdings, Ucommune International, and Bowlero Corp are among the gainers. Cuentas, WEBUY GLOBAL, SolarEdge Technologies, Processa Pharmaceuticals, Asset Entities, SeaStar Medical Holding Corporation, Arcutis Biotherapeutics, Atreca, Spectral AI, and Intuitive Surgical are among the losers.

Portfolio Pulse from Lisa Levin

October 20, 2023 | 11:42 am

Arcutis Biotherapeutics is selling 32.5 million shares of common stock at $2.50 per share and pre-funded warrants to purchase 7.5 million shares of common stock at $2.4999 per warrant. The offering is expected to raise $100 million.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 6:41 am

Several healthcare stocks experienced significant movement in Thursday's after-market session. Notable gainers included American Well (AMWL), Comera Life Sciences (CMRA), Generation Bio (GBIO), Applied Molecular (AMTI), HOOKIPA Pharma (HOOK), and GRI Bio (GRI). On the other hand, Atreca (BCEL), Processa Pharma (PCSA), Ontrak (OTRKP), Bio-Path Hldgs (BPTH), Arcutis Biotherapeutics (ARQT), and Intuitive Surgical (ISRG) saw their stock prices fall.

Portfolio Pulse from Benzinga Insights

October 19, 2023 | 9:31 pm

Arcutis Biotherapeutics, Inc. has announced a proposed public offering of $100 million. The company plans to use the net proceeds from the offering for general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 8:10 pm

Arcutis Biotherapeutics (NASDAQ:ARQT) has received a mix of bullish and indifferent ratings from analysts in the last quarter. The average price target is $34.83, which is significantly higher than the current price of $3.3701. However, this target represents a 28.19% decrease from the previous average price target of $48.50.

Portfolio Pulse from Benzinga Insights

October 13, 2023 | 3:00 pm

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has presented new data from its ARRECTOR Phase 3 trial of roflumilast foam 0.3% for the treatment of adults and adolescents with scalp and body psoriasis. The data shows significant improvements in both scalp and body psoriasis across all efficacy endpoints compared to vehicle. The results were presented at the EADV Congress held in Berlin. The company's Chief Medical Officer, Patrick Burnett, stated that the data suggests roflumilast foam may be an important topical treatment option.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:04 pm

Goldman Sachs analyst Jonathan Block has downgraded Arcutis Biotherapeutics (NASDAQ:ARQT) from Buy to Neutral and lowered the price target from $32 to $6.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 10:15 am

The FDA has approved Arcutis Biotherapeutics' supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis in children aged 6 to 11 years.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:02 pm

Despite a general downturn in the US stock market, several companies saw significant gains. Intercept Pharmaceuticals shares climbed 77.3% after Alfasigma agreed to acquire the company. Immunovant shares surged 75.6% following the announcement of initial IMVT-1402 Phase 1 SAD and 300 mg subcutaneous MAD results. ARS Pharmaceuticals jumped 18.8% after Director Rajeev Shah acquired a total of 2,700,000 shares. Roivant Sciences shares rose 17% following the announcement of initial IMVT-1402 Phase 1 SAD and 300 mg subcutaneous MAD results. Fisker shares jumped 14.2% after the company announced plans to ramp up deliveries.

Portfolio Pulse from Lisa Levin

September 26, 2023 | 2:49 pm

Analysts have provided bullish ratings for Arcutis Biotherapeutics (NASDAQ:ARQT) in the last quarter. According to 6 analysts offering 12-month price targets in the last 3 months, Arcutis Biotherapeutics has an average price target of $42.17, a decrease from the previous average price target of $65.00.

Portfolio Pulse from Benzinga Insights

September 25, 2023 | 8:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.